Labex IGO gathers immunologists in transplantation and oncology but also immunologists and specialists of oncogenesis and nuclear oncology divided among 13 scientific teams in Nantes, Rennes, Angers and Brest. It benefits also from the support of clinical and industrial partners.

Labex IGO was labeled during the second round of the call “LABEX” (Feb. 2012). This call aims to distribute significant resources to French laboratories to increase their international visibility, to attract researchers of international renown and to develop an integrated research, training and valorization of highest level.

Labex IGO aims to develop new immunotherapies in oncology and transplantation by :

The IGO consortium aims to generate several deliverables with major scientific, therapeutic and pharmaceutical impact. From a conceptual standpoint, identification of new pathways underlying tumor immune escape, operational tolerance and cell resistance to immunomodulating or depleting treatments should yield high impact publications and new immune targets with prognostic and therapeutic relevance.

From a clinical standpoint, the Labex will help strengthen the rationale and extend indications of current immunotherapies, that address unmet medical needs, and create opportunities for IGO industrial partners (> 15) to enrich their portfolio of molecules or clinical indications. Importantly, a major goal of IGO will be to assess a wide range of new combination approaches that cannot be easily implemented by private companies (eg due to intellectual property or regulatory constraints). Obtention of strong preclinical proof of their efficacy at the academic level (ie by the IGO partners) should foster their further industrial development, and could generate a wide range of new strategies with enhanced therapeutic benefit. Finally, the Labex IGO should have a major impact on the structuration of the biomedical community, as it will federate the laboratories in western France working in immunology, oncology, transplantation and autoimmunity, strengthen their overall coherence, international visibility and attractiveness. Furthermore IGO will contribute to the development of collaborations (eg in cellular therapies and monitoring approaches) with teams working on cardiovascular genetics and regenerative medicine. In this regard, the IGO consortium should help create a world-class excellence institute dedicated to development of personalized medicines, one of the priorities of the French national strategy of research and innovation (SNRI).

  • Identifying new targets and accelerating preclinical evidences of efficacy

  • Improving cellular immunotherapies efficacy

  • Developing immune-depletive and modulatory strategies

Photo I. Anegon

Labex IGO is led by Dr. Ignacio ANEGON (INSERM U1064 / CRTI)  

Your contacts

Laurence WolffGenerale delegate

Laurence Wolff IRS-UN, 4ème étage 8, Quai Moncousu BP 70721 Nantes - Laurence Wolff

Financial assistant

Giancarlo Espejo IRS-UN, 4ème étage 8, Quai Moncousu BP 70721 Nantes - Giancarlo Espejo

Mode de citation du Labex IGO dans les publications

Nous vous rappelons que, pour toutes les équipes du Labex IGO (que le projet sur lequel porte la publication soit ou non financé par le Labex IGO), l'appartenance au Labex IGO peut (et devrait) être systématiquement indiquée dans la liste des auteurs sous la forme: Laboratoire X (EA, INSERM, CNRS), LabEx IGO, Université/Hôpital Y, Ville, France. Pour les publications issues de projets financés par le Labex IGO (fonctionnement, salaire...) il faut citer le financement dans les remerciements: This work has been carried out thanks to the support of the LabEx IGO project (n° ANR-11-LABX-0016-01) funded by the «Investissements d’Avenir» French Government program, managed by the French National Research Agency (ANR)". Pour les publications issues de projets non financés par le Labex IGO mais dans le périmètre du Labex IGO, le Labex IGO peut être cité de la façon suivante: This work was realized in the context of the LabEX IGO program supported by the National Research Agency via the investment of the future program ANR-11-LABX-0016-01”